StageZero Life Sciences Provides Update on Cease Trade Order

StageZero Life Sciences, Ltd. (TSX:SZLS)(OTCQB:SZLSF), a healthcare company specializing in mRNA multi-cancer diagnostics, has announced that it remains under a Failure to File Cease Trade Order (FFCTO). This follows earlier press releases from April regarding delayed filings of its 2023 financials. The delay was due to insufficient resources to pay auditors to complete the audit.

The Ontario Securities Commission has given StageZero until July 3 to submit the necessary documents. Although the company aims to file ahead of this deadline, it will not meet the originally referenced May 31 deadline.

The FFCTO prohibits any trading of the company's securities in Canada until the filings are completed and the order is revoked. StageZero confirms that there is no additional undisclosed material information.